Organoid and microfluidics-based platforms for drug screening in COVID-19.
Drug Discov Today
; 27(4): 1062-1076, 2022 04.
Article
in English
| MEDLINE | ID: covidwho-1587950
ABSTRACT
Proposing efficient prophylactic and therapeutic strategies for coronavirus 2019 (COVID-19) requires precise knowledge of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogenesis. An array of platforms, including organoids and microfluidic devices, have provided a basis for studies of SARS-CoV-2. Here, we summarize available models as well as novel drug screening approaches, from simple to more advanced platforms. Notably, organoids and microfluidic devices offer promising perspectives for the clinical translation of basic science, such as screening therapeutics candidates. Overall, modifying these advanced micro and macro 3D platforms for disease modeling and combining them with recent advances in drug screening has significant potential for the discovery of novel potent drugs against COVID-19.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Organoids
/
Microfluidics
/
Drug Evaluation, Preclinical
/
SARS-CoV-2
/
COVID-19 Drug Treatment
/
Models, Biological
Type of study:
Prognostic study
Topics:
Traditional medicine
Limits:
Animals
/
Humans
Language:
English
Journal:
Drug Discov Today
Journal subject:
Pharmacology
/
Drug Therapy
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS